Pricing

Aptevo Therapeutics Inc (APVO)

followers ยท
Sector: HEALTH CARE
Industry: BIOTECHNOLOGY & LIFE SCIENCES
SIC: PHARMACEUTICAL PREPARATIONS
CEO: Marvin L. White
Employees: 50
Web site: aptevotherapeutics.com
2401 4TH AVE., SUITE 1050, SEATTLE, WA, 98121
206-838-0500
Stock Split History
Date Ratio
2020-03-27 1:14
2024-03-06 1:44
All 13F Filers Prior Change Hedge Funds 1 Prior Change
Aptevo Therapeutics Inc. focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. Its lead clinical candidate is APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelodysplastic syndrome. The company also has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527.
Please log in first to see chart
InvestorHistoryShares Held or Principal AmtMarket Value% of PortfolioPrevious % of PortfolioRankChange in Shares% OwnershipQtr 1st OwnedEst. Avg PriceSourceSource DateDate Reported
No data available